Nebivolol is a novel β1-adrenoceptor blocking drug with an unusual haemodynamic profile unlike that of classical β-blockers. In dogs and in healthy volunteers, it decreases blood pressure and heart rate but improves left ventricular function. We studied 10 male patients with coronary artery disease and heart failure (mean ejection fraction 46%). A Swan-Ganz catheter was placed into the pulmonary artery and the mean blood pressure, heart rate, pulmonary artery pressure, pulmonary wedge pressure, right atrial pressure, cardiac output and stroke volume were measured at rest and on exertion before and after 7 days’ treatment with oral nebivolol 5 mg/day. Whereas the blood pressure and the heart rate decreased significantly, the pulmonary artery and wedge pressures and right atrial pressure and cardiac output did not change during treatment. The stroke volume increased significantly. The maintained cardiac output cannot be explained by any changes in pre- or afterload; instead, a positive inotropic mechanism may be the explanation.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Alderman J, Grossman W. Are beta-adrenergic-blocking drugs useful in the treatment of dilated cardiomyopathy?. Circulation 71: 854–857, 1985
Braunwald E, Sonnenblick EH (Eds). Heart failure, pp. 1–13, Raven Press, New York, 1984
Burkart F, Pfisterer M, Steinmann E. Wirkungen von Bisoprolol — im Vergleich zu Metoprolol und Bufuralol — auf die linksventrikuläre Hämodynamik in Ruhe und unter Belastung bei chronischer koronarer Herzkrankheit. Journal of Cardiovascular Pharmacology 8 (Suppl. 11): 89–93, 1986
De Crée J, Geukens H, Cobo C, Verhaegen H. Subacute hemodynamic effects of nebivolol in man at rest and during exercise. Angiology 6: 440–448, 1987
De Crée J, Geukens H, Leempoels J, Verhaegen H. Haemodynamic effects in man during exercise of a single oral dose of nebivolol (R 67 555), a new beta-1-adrenoceptor blocking agent: a comparative study with atenolol, pindolol and propranolol. Drug Development Research 8: 109–117, 1986
Pauwels P, Gommeren W, Van Lommen G, Janssen P, Leysen J. The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers. Molecular Pharmacology 34: 843–851, 1988
Shanes JG. Beta-blockade — rational or irrational therapy for congestive heart failure?. Circulation 76: 971–973, 1987
Stokholm KH, Lund JD, Trap-Jensen J. Immediate haemodynamic effects of atenolol, bopindolol and placebo: a double blind crossover study of the partial agonist activity of bopindolol. Current Opinion in Cardiology 3 (Suppl. 2): 89–91, 1988
Van Bortel L, Schiffers P, Mooy J. Invasive hemodynamics of nebivolol in hypertensive patients. A preliminary report. International Symposium on Cardiovascular Disease and Beta-Adrenoceptor Function, Antwerp, Belgium, pp. 46–47, Oct 8, 1988
Van de Water A, Xhonneaux R, Reneman R, Janssen P. Cardiovascular effects of dl-nebivolol and its enantiomers. A comparison with those of atenolol. European Journal of Pharmacology 156: 95–103, 1988
Xhonneux R, de Reese R, Van Dael L, Reneman R. The blood pressure lowering effect of dl-nebivolol in spontaneously hypertensive rats — the potentiating action of 1-nebivolol and d-nebivolol and some other compounds. International Symposium on Cardiovascular Disease and Beta-Adrenoceptor Function, Antwerp, Belgium, pp. 16–17, Oct 8, 1988
About this article
Cite this article
Brune, S., Tebbe, U., Schmidt, T. et al. Haemodynamic Effects of Nebivolol in Patients with Coronary Artery Disease. Drug Invest 3, 64–68 (1991). https://doi.org/10.1007/BF03258266
- Cardiac Output
- Stroke Volume
- Pulmonary Artery Pressure
- Atrial Pressure